Literature DB >> 32376089

Providing Incentive for Emergency Physician X-Waiver Training: An Evaluation of Program Success and Postintervention Buprenorphine Prescribing.

Sean D Foster1, Kathleen Lee2, Christopher Edwards3, Arthur P Pelullo4, Utsha G Khatri3, Margaret Lowenstein5, Jeanmarie Perrone3.   

Abstract

STUDY
OBJECTIVE: Emergency department (ED) initiation of buprenorphine for patients with opioid use disorder increases treatment engagement but remains an uncommon practice. One important barrier to ED-initiated buprenorphine is the additional training requirement (X waiver). Our objective is to evaluate the influence of a financial incentive program on emergency physician completion of X-waiver training. Secondary objectives are to evaluate the program's effect on buprenorphine prescribing and to explore physician attitudes toward the incentive.
METHODS: We conducted a prospective, observational cohort study set in 3 urban academic EDs before and after implementation of a financial incentive program providing $750 for completion of X-waiver training. We describe program participation as well as rates of buprenorphine prescribing per opioid use disorder-related encounter before and after the intervention period, using electronic health record data. We also completed a postintervention physician survey assessing attitudes about the incentive program.
RESULTS: Overall, 89% of eligible emergency physicians (56/63) completed the X-waiver training during the 6-week incentive period. In the 5 months after the incentive, buprenorphine prescribing per opioid use disorder-related encounter increased from 0.5% to 16% (Δ 15%; 95% confidence interval 10.6% to 19.9%), with substantial variability across sites (range 8% to 22% of opioid use disorder-related encounters). In a postintervention survey, 67% of participating physicians indicated that they would have completed the training for a lower amount.
CONCLUSION: A financial incentive paying approximately half the clinical rate was effective in promoting emergency physician X-waiver training. The effect on ED-based buprenorphine prescribing was positive but variable across sites, and likely dependent on the availability of additional supports.
Copyright © 2020 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32376089     DOI: 10.1016/j.annemergmed.2020.02.020

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  5 in total

1.  Sustained Implementation of a Multicomponent Strategy to Increase Emergency Department-Initiated Interventions for Opioid Use Disorder.

Authors:  Margaret Lowenstein; Jeanmarie Perrone; Ruiying A Xiong; Christopher K Snider; Nicole O'Donnell; Davis Hermann; Roy Rosin; Julie Dees; Rachel McFadden; Utsha Khatri; Zachary F Meisel; Nandita Mitra; M Kit Delgado
Journal:  Ann Emerg Med       Date:  2021-12-23       Impact factor: 5.721

2.  Improving transitions of care for patients initiated on buprenorphine for opioid use disorder from the emergency departments in King County, Washington.

Authors:  Callan Elswick Fockele; Herbert C Duber; Brad Finegood; Sophie C Morse; Lauren K Whiteside
Journal:  J Am Coll Emerg Physicians Open       Date:  2021-03-23

3.  Improving Uptake of Emergency Department-initiated Buprenorphine: Barriers and Solutions.

Authors:  Timothy D Kelly; Kathryn F Hawk; Elizabeth A Samuels; Reuben J Strayer; Jason A Hoppe
Journal:  West J Emerg Med       Date:  2022-07-11

4.  "This is part of emergency medicine now": A qualitative assessment of emergency clinicians' facilitators of and barriers to initiating buprenorphine.

Authors:  Elizabeth M Schoenfeld; William E Soares; Emily M Schaeffer; Jacob Gitlin; Kimberly Burke; Lauren M Westafer
Journal:  Acad Emerg Med       Date:  2021-09-07       Impact factor: 3.451

Review 5.  Misalignment of Stakeholder Incentives in the Opioid Crisis.

Authors:  Alireza Boloori; Bengt B Arnetz; Frederi Viens; Taps Maiti; Judith E Arnetz
Journal:  Int J Environ Res Public Health       Date:  2020-10-16       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.